Skip to content

Study · Animal study (in vivo) · mouse · 2026

4 results

Abaloparatide increases bone mass by increasing bone formation regardless of alendronate pretreatment in mice.

Makino A, Hasegawa T, Yamamoto T, Takagi H, Iijima T, Amizuka N

Journal of oral biosciences18 Nov 2025

PMID41714054 (opens in a new tab)DOI10.1016/j.job.2025.100708 (opens in a new tab)PepBankPUB-41714054
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, abaloparatide increased femoral bone mineral density at all alendronate doses, with effects equal to or greater than without pretreatment.

    In plain wordsIn mice, abaloparatide increased thigh bone density, with effects equal to or greater than in mice without alendronate pretreatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral bone mineral density
    Study

    mousen: not reported in source

    Mice with or without alendronate pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    ABL increased femoral bone mineral density at all ALN doses, with effects equal to or greater than those observed in mice without ALN.
    1 context sentence
    Summary · context
    Mice were administered alendronate (ALN) at different doses for 21 days, followed by 28 days of ABL.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, abaloparatide increased ALPase-positive osteoblasts irrespective of alendronate pretreatment.

    In plain wordsIn mice, abaloparatide increased bone-forming cells with the ALPase marker, with or without alendronate pretreatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseALPase-positive osteoblasts
    Study

    mousen: not reported in source

    Mice with or without alendronate pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Histological analysis demonstrated that ABL increased ALPase- and PHOSPHO1-positive osteoblasts, irrespective of ALN pretreatment.
    1 context sentence
    Summary · context
    Mice were administered alendronate (ALN) at different doses for 21 days, followed by 28 days of ABL.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, abaloparatide increased PHOSPHO1-positive osteoblasts irrespective of alendronate pretreatment.

    In plain wordsIn mice, abaloparatide increased bone-forming cells with the PHOSPHO1 marker, with or without alendronate pretreatment.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePHOSPHO1-positive osteoblasts
    Study

    mousen: not reported in source

    Mice with or without alendronate pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Histological analysis demonstrated that ABL increased ALPase- and PHOSPHO1-positive osteoblasts, irrespective of ALN pretreatment.
    1 context sentence
    Summary · context
    Mice were administered alendronate (ALN) at different doses for 21 days, followed by 28 days of ABL.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, abaloparatide increased TRAP-positive osteoclasts, with attenuation at higher alendronate pretreatment doses.

    In plain wordsIn mice, abaloparatide increased bone-resorbing cells with the TRAP marker, but higher alendronate pretreatment doses weakened this increase.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTRAP-positive osteoclasts
    Study

    mousen: not reported in source

    Mice with or without alendronate pretreatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    However, the increase in TRAP-positive osteoclasts by ABL was attenuated at higher ALN doses.
    1 context sentence
    Summary · context
    Mice were administered alendronate (ALN) at different doses for 21 days, followed by 28 days of ABL.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.